Search Within

Guido Dalbagni

  1. "General Medicine Services"
Formats
  1. Journal Article (3)
  2. Meeting Abstract (2)
Groups
  1. Department of Medicine (5)
  2. General Medicine Services (5)
  3. Genitourinary Oncology Service (5)
  4. Hospital Medicine (5)
  5. Solid Tumor Oncology Division (5)
  6. Surgery (5)

More Groups

People
  1. Dean Bajorin (5)
  2. Jamie Riches (5)
  3. Bernard Bochner (4)
  4. Gopakumar Iyer (4)
  5. Hikmat Al-Ahmadie (4)
  6. Sherri Donat (4)

More People

Years
  1. 2018 (1)
  2. 2016 (2)
  3. 2011 (1)
  4. 2009 (1)
Publications
  1. Journal of Clinical Oncology (3)
  2. Cancer (1)
  3. Journal of Pathology (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. Wiley Blackwell (2)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer
    Journal Article

    Iyer, G.; Balar, A. V.; Milowsky, M. I.; Bochner, B. H.; Dalbagni, G.; Donat, S. M.; Herr, H. W.; Huang, W. C.; Taneja, S. S.; Woods, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC)
    Meeting Abstract

    Iyer, G.; Balar, A. V.; Milowsky, M. I.; Huang, W. C.; Woods, M.; Donat, S. M.; Herr, H. W.; Dalbagni, G.; Bochner, B. H.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Multicenter prospective phase II trial of neoadjuvant (neo) dose dense gemcitabine and cisplatin (DD-GC) in patients (pts) with muscle-invasive bladder cancer (MIBC)
    Meeting Abstract

    Balar, A. V.; Iyer, G.; Milowsky, M. I.; Huang, W. C.; Woods, M.; Donat, S. M.; Herr, H. W.; Dalbagni, G.; Bochner, B. H.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma
    Journal Article

    Al-Ahmadie, H. A.; Iyer, G.; Janakiraman, M.; Lin, O.; Heguy, A.; Tickoo, S. K.; Fine, S. W.; Gopalan, A.; Chen, Y. B.; Balar, A.; more...
    Journal of Pathology (2011)

    Fulltext@MSK | Save
  • Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma
    Journal Article

    Gallagher, D. J.; Milowsky, M. I.; Iasonos, A.; Maluf, F. C.; Russo, P.; Dalbagni, G.; Donat, M. S.; Boyle, M. G.; Zheng, J.; Riches, J.; more...
    Cancer (2009)

    Fulltext@MSK | Save